Canada· CA-DIN-02243173
DEFINITY
A perflutren, phospholipid-mikrosphären product containing perflutren, registered in Canada by LANTHEUS MI CANADA INC. The same ATC class is registered in 9 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Perflutren, phospholipid-mikrosphären is registered in 9 of 19 countries.
Countries holding a registration under ATC V08DA04 (perflutren, phospholipid-mikrosphären), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 5 of them publish a price we can compare per daily dose
Perflutren, phospholipid-mikrosphären · ATC V08DA04
9 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- PERFLUTREN
- Manufacturer
- LANTHEUS MI CANADA INC
- Country
- Canada (CA)
- ATC code
- V08DA04
- ATC class
- Perflutren, Phospholipid-Mikrosphären
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
159 interactions on record for perflutren, phospholipid-mikrosphären.
Graded by severity as the source publishes them — 36 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Perflutren, phospholipid-mikrosphären · interactions on record
159 records
- 36 severe
- 121 moderate
- 2 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- PapaverinC04AX38severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Perflutren, phospholipid-mikrosphären in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLUMINITYLantheus EU Limited, Shannon
- SpainLUMINITY 150 MICROLITROS/ML GAS Y DISOLVENTE PARA SOLUCIÓN PARA DISPERSIÓN INYECTABLE Y PARA PERFUSIÓNLantheus Eu Limited
- United KingdomLuminity 225microlitres/1.5ml gas and solvent for dispersion for injection vialsPharmanovia Benelux B.V.
- United StatesDefinityLantheus Medical Imaging, Inc.
- FinlandLuminityLantheus EU Limited
- SwedenLuminity 150 mikroliter/ml Injektions-/infusionsvätska, dispersionLantheus EU Limited
- BelgiumLuminity 150 µl/mlLantheus EU
- IcelandLuminityLantheus EU Limited
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Optison
- Iceland · Optison
- Liechtenstein · Optison
- Norway · Optison
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e54ee007-5819-44d7-8254-630ee77a7867 GET /v1/drugs/e54ee007-5819-44d7-8254-630ee77a7867?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02243173",
"form": "SUSPENSION",
"class": "Human",
"routes": [
"INTRAVENOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "V08DA04",
"schedule": [
"Prescription"
],
"drug_code": "67049",
"strengths": [
"150 MCL"
],
"ahfs_class": null,
"substances": [
"PERFLUTREN"
],
"product_categorization": null
}See everything about perflutren, phospholipid-mikrosphären.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.